Episode 91: The Story of Motilent and GI Imaging 🩺

This week, James is Joined by Alex Menys, CEO and founder of Motilent. Motilent’s mission is to change the way we see the gut. We have spent the last 5 years developing new imaging technology that is helping researchers and clinicians understand how the digestive tract works. Our key clinical focus area is Crohn’s Disease, a debilitating inflammatory condition affecting people of all ages and our first product GIQuant aims to help clinicians to identify earlier when patients stop responding to immunotherapy.

Alex founded Motilent in 2013 to expedite collaborative research in his field of medical image analysis for gastrointestinal (GI) disorders. Since then, Motilent has grown to working across a range of GI specialties in research and has produced it's first clinically available product for Crohn's disease monitoring - GIQuant. Alex holds master degrees in Biochemistry and Medical Physics, a PhD in MRI imaging and spent 2 years on the board of an AIM listed UK medical device company.

https://www.motilent.co.uk/ | https://www.linkedin.com/in/alex-menys-83675b75/

js@somx.co.uk | www.jamessomauroo.com